To Comply With FDA, 23andMe Won't Give New Customers Genetic Analysis
The personal genetics startup 23andMe announced this evening that it will stop giving new customers access to health reports tied to their genes, after being warned by the FDA over compliance issues.
Context & Ripple Effects
Two weeks after the FDA told the Google-backed startup to halt sales of its $99 DNA kits over missing marketing clearance — a move 23andMe answered with an apology for being slow to respond (an apology for being slow) — the company has now conceded the regulator's core point. New customers will still get their raw genetic data, but not the health reports built on top of it.
The concession matters because the health readouts were the product's main differentiator; the FDA's November 25 halt order framed the kits as unapproved medical devices, and 8 national outlets from the Washington Post to Gizmodo picked up tonight's retreat, making this the reference case for how the agency handles consumer genetics.
First-order effects
- New 23andMe customers pay the same price for a stripped-down service: raw data and ancestry information without the disease-risk analyses that defined the kit, while existing customers' access is untouched.
- The FDA gets compliance without a court fight — 23andMe's voluntary suspension removes the immediate enforcement question raised on November 25.
Second-order effects
- Rival direct-to-consumer genetics firms selling health interpretations now operate under a demonstrated enforcement path: the FDA has shown it will force a market leader to pull features, so smaller players must either pursue clearances or narrow their own claims.
- The value proposition of the $99 kit weakens relative to its price, pressuring 23andMe to justify the purchase through ancestry content and raw-data utility rather than medical insight.
Third-order effects
- If the pattern holds, consumer genomics consolidates around companies willing to run the FDA's device-clearance gauntlet test-by-test, raising capital barriers and pushing hobbyist-style health interpretation toward clinical or research channels.
- The episode establishes a template likely to extend to adjacent consumer health hardware and apps: any product inferring disease risk from personal data becomes regulable, regardless of whether it ships as a lab service or software.
The trend: Direct-to-consumer health products are being absorbed into the FDA's medical-device regime, forcing startups to choose between regulatory clearance and a diminished consumer offering.